Literature DB >> 21788137

N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands.

Samuel D Banister1, David T Yoo, Sook Wern Chua, Jinquan Cui, Robert H Mach, Michael Kassiou.   

Abstract

A series of racemic N-arylalkyl-2-azaadamantan-1-ols (9-15) and the corresponding deoxygenated, achiral N-arylalkyl-2-azaadamantanes (23-29) were synthesized and screened in competition binding assays against a panel of CNS targets. Adamantyl hemiaminals 9-15 displayed generally low affinity for both σ(1) (K(i) values= 294-1950 nM) and σ(2) receptors (K(i) values=201-1020 nM), and negligible affinity for 42 other CNS proteins. Deoxygenation of 9-15 to give the corresponding achiral azaadamantanes 23-29 greatly improved affinity for σ(1) (K(i) values=8.3-239 nM) and σ(2) receptors (K(i) values=34-312 nM).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788137     DOI: 10.1016/j.bmcl.2011.07.028

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

Review 1.  Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity.

Authors:  Markos-Orestis Georgiadis; Olga Karoutzou; Angeliki-Sofia Foscolos; Ioannis Papanastasiou
Journal:  Molecules       Date:  2017-08-25       Impact factor: 4.411

2.  Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective.

Authors:  Antonino N Fallica; Valeria Pittalà; Maria N Modica; Loredana Salerno; Giuseppe Romeo; Agostino Marrazzo; Mohamed A Helal; Sebastiano Intagliata
Journal:  J Med Chem       Date:  2021-06-02       Impact factor: 7.446

3.  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.

Authors:  Satya Narayan; Srinivasa Ramisetti; Aruna S Jaiswal; Brian K Law; Ashona Singh-Pillay; Parvesh Singh; Shantu Amin; Arun K Sharma
Journal:  Eur J Med Chem       Date:  2018-10-23       Impact factor: 6.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.